Self-Dissolving Micropiles for the Percutaneous Absorption of Recombinant Human Growth Hormone in Rats
| Autor: | Yukako Ito, Nobuyuki Sugioka, Keiji Shiroyama, Yoshinori Ohashi, Kanji Takada |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Skin Absorption Pharmaceutical Science Enzyme-Linked Immunosorbent Assay Absorption (skin) law.invention chemistry.chemical_compound law Internal medicine medicine Animals Rats Wistar Pharmacology Human Growth Hormone Human growth hormone General Medicine Recombinant Proteins Rats Bioavailability Dextran Endocrinology chemistry Area Under Curve Injections Intravenous Percutaneous absorption Drug delivery Recombinant DNA Nanoparticles Delivery system Half-Life |
| Zdroj: | Biological & Pharmaceutical Bulletin. 31:1631-1633 |
| ISSN: | 1347-5215 0918-6158 |
| DOI: | 10.1248/bpb.31.1631 |
| Popis: | The feasibility of self-dissolving micropiles (SDMP) as a percutaneous delivery system of recombinant human growth hormone (rhGH) has been studied in rats using SDMP where dextran was used as a base. After mixing dextran solution with rhGH, SDMPs were prepared by pulling with polypropyrene tips. The mean weight, length and diameter were 0.68+/-0.05 mg, 3.2+/-0.5 mm and 0.6+/-0.2 microm, respectively. To evaluate the bioavailability (BA) of rhGH percutaneously administered by SDMP, an absorption experiment was performed in rats. RhGH SDMPs were inserted into the rats skin, 200 microg kg(-1), and plasma rhGH levels were measured by an ELISA method. Peak plasma rhGH level, 132.8+/-11.8 ng ml(-1), appeared at 0.8+/-0.2 h. By comparing the plasma rhGH levels vs. time profiles after the administration of SDMP and intravenous injection of rhGH solution, 5 microg kg(-1), BA of rhGH from SDMP was calculated to be 87.5%. Theses results may suggest that SDMP can be used as a novel percutaneous drug delivery system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|